决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies.
为解决免疫逃逸,多特异性 CAR-T 细胞策略利用能特异性结合恶性细胞上多个受体的天然配体。
为应对免疫逃逸,多特异性CAR-T细胞策略采用可特异性结合恶性细胞多个受体的天然配体。在此背景下,我们提出一种分体式CAR设计,由T细胞表达的通用受体和基于配体的开关分子组成,可保留APRIL和BAFF等配体的天然三聚体结构。优化铰链及开关标记位点后,分体式CAR-T细胞可维持配体天然构象,促进靶癌细胞与CAR-T细胞之间最佳免疫突触形成。在雌性小鼠的多种B细胞恶性肿瘤模型中,我们的CAR-T策略展现抗肿瘤活性;在常规CAR-T疗法后发生抗原丢失或转换时,该策略可能预防免疫逃逸。这种基于配体的分体式CAR设计为优化CAR识别提供了新思路,可增强疗效并有望提高临床转化安全性,也可能广泛适用于基于天然受体或配体的细胞疗法。
To address immune escape, multi-specific CAR-T-cell strategies use natural ligands that specifically bind multiple receptors on malignant cells. In this context, we propose a split CAR design comprising a universal receptor expressed on T cells and ligand-based switch molecules, which preserves the natural trimeric structure of ligands like APRIL and BAFF. Following optimization of the hinges and switch labeling sites, the split-design CAR-T cells ensure the native conformation of ligands, facilitating the optimal formation of immune synapses between target cancer cells and CAR-T cells. Our CAR-T-cell strategy demonstrates antitumor activities against various B-cell malignancy models in female mice, potentially preventing immune escape following conventional CAR-T-cell therapies in the case of antigen loss or switching. This ligand-based split CAR design introduces an idea for optimizing CAR recognition, enhancing efficacy and potentially improving safety in clinical translation, and may be broadly applicable to cellular therapies based on natural receptors or ligands.
MEMBER ACCOUNT
登录成功会直接打开下一页。